Antigen-specific CD8 + T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape. Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide-major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex. This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation. Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact. Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC. These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.
Antigen-specific CD8 + T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape. Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide-major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex. This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation. Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact. Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC. These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.
T-cell tolerance plays an important part in tumor escape 1 and is one of the chief obstacles limiting the effect of cancer vaccines. Antigenpresenting cells (APCs) are primarily responsible for the induction of tumor-induced T-cell tolerance 2, 3 . We and others 4, 5 have identified a group of Gr-1 + CD11b + MDSCs that are primarily responsible for tumor-associated CD8 + T-cell tolerance. These are immature cells, comprising precursors of macrophages, granulocytes, dendritic cells (DCs) and myeloid cells at earlier stages of differentiation, and they have the ability to suppress immune response in vitro through direct cell-cell contact (reviewed in refs. [6] [7] [8] [9] . Accumulation of similar cells has been described in individuals with cancer [10] [11] [12] . MDSCs induce antigen-specific MHC class I-restricted tolerance of CD8 + T cells in vivo 4 . This pathway may underlie antigen-specific inhibition of immune response in cancer and may explain the difficulties in maintaining the antigen-specific immune response after vaccination in individuals with cancer. The mechanism of MDSC-induced CD8 + T-cell tolerance, however, remains unclear.
There are two basic mechanisms of inducing T-cell tolerance: deletion and anergy. Existing data in vitro and in vivo indicate that MDSCs do not induce T-cell death or the deletion of antigen-specific T cells [4] [5] [6] [7] [8] [9] . Although much is known about the biochemical basis of T-cell anergy, the antigen-specific nature of T-cell tolerance is less understood 13, 14 . Using an experimental model in vivo, we show here that MDSCs, by generating reactive oxygen species (ROS) and peroxynitrite, induce modification of TCR and CD8 molecules, resulting in the loss of ability of CD8 + T cells to bind pMHC and the induction of antigen-specific non-responsiveness of peripheral CD8 + T cells. Our findings identify a previously unknown mechanism of inducing T-cell tolerance in cancer and may be applicable to many pathological conditions (such as infection, inflammation, trauma) associated with the accumulation of MDSCs overproducing peroxynitrite.
RESULTS

MDSCs disrupt pMHC binding to CD8 + T cells
We used an experimental model in which the direct effect of MDSCs on antigen-specific CD8 + T cells could be evaluated in vivo (Supplementary Fig. 1 online) . In this model, OT-1 T cells (CD45.1 À ) were transferred to naive CD45.1 + congenic recipients. MDSCs from EL-4 tumor-bearing mice were transferred 2 d later and mice were immunized with specific peptide. Lymph node cells were collected 10 d after immunization. By that time all transferred MDSCs either differentiated into mature myeloid cells or died (ref. 15 and data not shown) and did not directly interfere with any assay performed in lymph nodes. Donor CD45.1 À CD8 + T cells from mice that received MDSCs had substantially lower ability to bind specific pMHC-Ig dimers than cells from control mice (Fig. 1a,b) . A similar effect was observed in a different experimental system in which T cells from 2C transgenic mice were adoptively transferred to naive congenic mice and 2C-specific peptide was used for immunization ( Supplementary  Fig. 2a online) . Repeated experiments showed that MDSC administration did not affect the expression of TCR or CD8 molecules on the surface of T cells ( Fig. 1c and Supplementary Fig. 2 ).
Lymph node cells isolated from mice treated with MDSCs were re-stimulated in vitro with increasing concentrations of the specific peptides. The number of CD8 + T cells producing interferon-g (IFN-g) was evaluated by ELISPOT assay. CD8 + T cells from MDSCtreated mice did not respond to the specific peptide. The response was not improved even by a 50-fold increase in peptide concentration (Fig. 1d) . These data were confirmed in a cytotoxic T lymphocyte (CTL) assay against EL-4 and T2-K b target cells. In both experimental models (OT-1 and 2C), T cells from control immunized mice showed peptide-specific CTL activity against target cells. By contrast, T cells from mice treated with MDSCs did not recognize specific targets. Increasing the concentration of the peptide used to load target cells did not improve CTL killing ( Fig. 1e and Supplementary  Fig. 2c online) .
To address the possible role of TCR affinity in MDSC-mediated CD8 + T-cell tolerance, we used three peptides with different affinity to the 2C TCR: SIYRYYGL (SIY) has high affinity, EQYKFYSV (DEV8) has intermediate affinity, and LSPFPFDL (P2CA) has low affinity 16, 17 SIY peptide induced a potent response of 2C CD8 + T cells and transfer of MDSCs completely abolished this response (Fig. 1f) . CD8 + T-cell response to DEV8 peptide was much weaker. It also was blocked by MDSCs. No response was detected against P2CA peptide.
Mechanism of disruption of pMHC binding to CD8 + T cells
Previous studies have shown that MDSCs produce large amounts of ROS 8 . To clarify the role of ROS in MDSC-induced T-cell tolerance in vivo, we used mice lacking gp91 phox , an essential component of the NADPH complex (ref. 18) . MDSCs from mice genetically deficient in gp91 phox (encoded by gp91 phox , also known as Cybb) have little or no ROS but maintain MHC class I expression (data not shown). In contrast to MDSCs from wild-type tumor-bearing mice, MDSCs isolated from gp91 phox-/-tumor-bearing mice did not induce CD8 + T-cell tolerance (Fig. 2a) .
After interaction with nitric oxide (NO), O 2 -forms peroxynitrite (ONOO À ) with a high biological activity 19 . MDSCs produce large amounts of peroxynitrite 20 . To evaluate the possible role of ONOO -in MDSC-mediated T-cell tolerance, mice that had undergone adoptive transfer of OT-1 T cells and MDSCs were treated with uric acid, a compound that specifically neutralizes peroxynitrite 21, 22 . Uric acid completely abrogated the tolerogenic effect of MDSCs (Fig. 2b) . A previous study has described the ability of uric acid in crystal form to activate APCs 23 , whereas we used a soluble form of uric acid. To evaluate directly the possible effect of uric acid on APC activation, mice were treated for 48 h with the acid, and the phenotype and function of DCs were evaluated. No differences between control and treated mice were found (data not shown).
In contrast to activated macrophages, MDSCs often do not show significant upregulation of nitric oxide 20, 24 . To elucidate the role of nitric oxide in MDSC-mediated T-cell tolerance, we used mice genetically deficient in inducible nitric oxide synthase (iNOS, encoded by iNOS, also known as Nos2). These mice cannot upregulate nitric oxide production in response to different stimuli; however, they retain basal nitric oxide production because of the activity of other NOS, primarily endothelial NOS (eNOS) 25 . MDSCs from iNOS -/-tumorbearing mice had the same ability to induce CD8 + T-cell tolerance as MDSCs from wild-type tumor-bearing mice (Fig. 2c) . These data indicated that upregulation of ROS but not nitric oxide was primarily responsible for MDSC-mediated CD8 + T-cell tolerance. Neutralization of peroxynitrite with urea completely abrogated MDSC-mediated decrease in the binding of the specific pMHC to CD8 + T cells in vitro (Fig. 2d) , suggesting that peroxynitrite has a critical role in the disruption of pMHC binding to CD8 + T cells.
To verify the possible role of peroxynitrite in CD8 + T cell tolerance, we used a donor of peroxynitrite, 3-morpholinosydnonimine (SIN-1). OT-1 T cells were pre-treated for 30 min with different concentrations (Fig. 3a,b) and it substantially reduced specific pMHC binding to CD8 + T cells (Fig. 3c) but did not affect the expression of TCR or CD8 on the T cell surface (Fig. 3d) . PHA-inducible T-cell proliferation was not affected (Fig. 3a) , whereas IFN-g production was reduced, although it remained substantially higher than in the control (Fig. 3b) . A higher dose of SIN-1 resulted in a progressive decrease in cell viability (data not shown) and T-cell proliferation (Fig. 3a) and complete abrogation of IFN-g production (Fig. 3b) . These data show that, at a relatively low dose, SIN-1 reduces the pMHC binding and blocks peptidespecific responses, but has a limited effect on nonspecific stimulation of CD8 + T cells. This effect is similar to that exerted by MDSCs in vivo.
Role of nitration of TCR complex in CD8 + T-cell tolerance
The main effect of peroxynitrite is its ability to modify proteins through oxidation or nitration of different amino acids. One of the main targets of peroxynitrite activity is tyrosine, which creates nitrotyrosine. Nitration of tyrosine is relatively stable 26 and has been shown to impede the function of the proteins through alteration of the hydrogen-bond, van der Waals and electrostatic network 27 . We considered that nitration of tyrosine in the pMHC-TCR complex might increase its rigidity and disable its integrity. Molecular modeling of the 2C TCR indicated that nitration of tyrosine at several sites in TCR and CD8 would markedly alter recognition of pMHC ( Supplementary  Figs. 3 and 4 online) . We tested whether MDSCs could cause nitration of TCR-CD8 in antigen-specific CD8 + T cells. Lymph node cells were isolated from mice after adoptive transfer of OT-1 T cells and MDSCs, and immunization. With gating on donor peptide-specific CD8 + V a2 + T cells and recipient CD8 + V 2 -T cells, nitrotyrosine on the cell surface was evaluated with a nitrotyrosine-specific antibody (Fig. 4a) . CD8 + V a2 + and CD8 + V a2 À cells from control immunized mice showed similar expression of nitrotyrosine. By contrast, CD8 + V a2 + cells from MDSC recipients had much more nitrotyrosine (Fig. 4a) . OT-1 CD8 + T cells were pre-activated with specific peptide for 72 h and then incubated for 48 h with MDSCs isolated from tumor-bearing mice. MDSCs substantially increased nitrotyrosine in OT-1 CD8 + cells (Fig. 4b,c) . MDSCs isolated from gp91 phox-/-but not iNOS -/-mice did not induce nitrotyrosine expression on the T-cell surface (Fig. 4b) . Treatment of MDSCs with the ROS inhibitor sodium dismutase (SOD) and the NOS inhibitor L-NMMA blocked the MDSC-inducible increase in nitrotyrosine (Fig. 4c) . L-NMMA inhibits the activity of both eNOS and iNOS, and thus reduces basal NO production 28 , which may explain the difference between these results and those obtained with iNOS -/-MDSCs.
We incubated activated OT-1 T cells with MDSCs for 48 h in the presence of specific peptide. T cells were isolated and whole-cell lysates were analyzed by immunoblotting with a nitrotyrosine-specific antibody. Treatment of T cells with MDSCs resulted in several bands positive for nitrotyrosine (Fig. 4d) . Treatment of the membranes with sodium dithionite, which causes chemical reduction of nitrotyrosine to aminotyrosine, completely eliminated binding (Fig. 4d) , indicating that bands detected indeed contained nitrotyrosine. We tested whether TCR and CD8 molecules could be the targets for MDSC-mediated nitration. Proteins were precipitated with antibody to TCR-b, CD8 or control IgG, subjected to electrophoresis, and then probed with a nitrotyrosine-specific antibody. MDSCs induced a substantial increase in nitrotyrosine in both TCR-b and CD8 (Fig. 4e) .
Interaction between MDSCs and CD8 + OT-1 T cells in the presence of specific peptide was evaluated by confocal microscopy. Almost all Gr-1 + MDSCs were positive for nitrotyrosine localized both on the membrane and in cytoplasm (Fig. 5a) . CD8 + T cells were negative for nitrotyrosine. After 5 h of incubation, direct contacts between Gr-1 + MDSCs and CD8 + OT-1 T cells were readily detectable (Fig. 5b) . Nitrotyrosine in CD8 + T cells was primarily localized on the membrane at the point of interaction between MDSCs and CD8 + T cells (Fig. 5c) . After 48 h incubation with MDSCs, diffuse membrane nitrotyrosine staining of CD8 + T cells was evident (Fig. 5d) .
We tested whether nitrotyrosine-positive CD8 + T cells could be found in lymph nodes from tumor-bearing hosts. We studied lymph nodes obtained from six individuals with breast or head and neck cancer. Only lymph nodes free of tumor cells were evaluated. As a control, lymphoid tissues (tonsils) from two tumor-free individuals were used. Very few nitrotyrosine-positive CD8 + T cells were found in control samples, whereas lymph nodes from individuals with cancer contained detectable nitrotyrosine-positive CD8 + T cells (Fig. 5e and Supplementary Fig. 5 online) . 
Reversal of MDSC-induced CD8 + T-cell tolerance
MDSC-induced CD8 + T-cell tolerance persisted for at least 3 weeks. The response in control mice gradually decreased with time ( Supplementary Fig. 6a ,b online); however, 22 d after immunization the peptide-specific response was still detectable in lymph nodes of control, but not MDSC-treated, mice ( Supplementary Fig. 6b ). Stimulation with peptide-loaded lipopolysaccharide (LPS)-activated mature DCs (mDCs) but not immature DCs (iDCs) overcame MDSC-induced T-cell tolerance (Fig. 6a) .
We examined whether CD8 + T-cell tolerance could be observed in tumor-bearing mice. These mice would have 'natural' tumor-associated antigens and MDSCs. We provided only the source of antigen-specific T-cells. Two types of tumor were used: EL-4 cells expressing ovalbumin (EG-7) and parental EL-4 tumors. We previously determined that both EL-4 and EG-7 tumors result in an accumulation of MDSCs, which can process and present OVA-derived epitope on their surface 4 . OT-1 T-cells were transferred to EL-4 and EG-7 tumor-bearing mice, and mice were killed 7 d later. Lymph nodes from control mice contained very few Gr-1 + cells, whereas lymph nodes from tumor-bearing mice were packed with these cells (Supplementary Fig. 7a ,b online) located in T-cell areas in direct contact with CD8 + T cells ( Supplementary  Fig. 7c ). Lymph node cells were stimulated with specific or control peptides and the responses were evaluated by IFN-g ELISPOT assay.
Control tumor-free mice demonstrated a low (because T cells were not activated in vivo) but clearly detectable specific response. A similar response was found in EL-4 tumor-bearing mice. By contrast, no specific response was observed in lymph nodes from EG-7 tumor-bearing mice (Fig. 6b) . The amount of nitrotyrosine in recipient V a2 -CD8 + T cells was similar in all groups of mice. It was, however, considerably higher in donor V a2 + CD8 + T cells from EG-7 tumor-bearing mice than in those from control or EL-4 tumor-bearing mice (Fig. 6c) .
To identify the potential role of peroxynitrite in this process, EG-7 tumor-bearing mice were treated with daily intraperitoneal (i.p.) injections of uric acid starting from the day of adoptive transfer of OT-1 T cells. After 7 d, lymph node cells were isolated and restimulated with control or specific peptides. In tumor-bearing mice, OT-1 CD8 + T cells lost the ability to respond to stimulation with specific peptide, as assessed by IFN-g ELISPOT (Fig. 6d) and CTL (Fig. 6e) assays. Treatment with uric acid completely prevented the development of T-cell tolerance (Fig. 6d,e) . To eliminate the possibility that uric acid can induce nonspecific T-cell activation, naive C57BL/6 mice were treated with daily uric acid i.p. injections for 7 d. Spleen and lymph node T cells were analyzed for the expression of CD25 and CD69 molecules and for proliferation in response to different stimuli. Treatment with uric acid did not result in activation of T cells ( Supplementary Fig. 8 online) .
We addressed the possibility that blocking peroxynitrite may improve the anti-tumor effect of a cancer vaccine in a non-transgenic experimental system. An MC38 tumor was established in C57BL/6 mice by subcutaneous (s.c.) injection of tumor cells. On day 10 after tumor inoculation, when tumors were palpable, mice were split into four groups with equal tumor size. Mice in the treatment group were immunized with DC-Ad-p53 vaccine as described 29 . Treatment with uric acid was started 3 d after the first immunization and was continued for 2 weeks. Control groups included mice treated with uric acid alone or vaccine alone, and untreated mice. Immunization of mice with established tumors resulted only in a temporal delay of tumor growth, which resumed 7 d after treatment had finished. Uric acid alone only marginally delayed tumor growth. By contrast, a combination of vaccination with uric acid resulted in a substantial delay in tumor growth (Fig. 6f) .
DISCUSSION
MDSCs are produced in response to various tumor-derived cytokines and represent a mixed population of myeloid cells at different stages of differentiation 7,10,30-32 . In addition to cancer, many pathological conditions including traumatic stress, bacterial and parasitic infections have been reported to have increased production of MDSCs [33] [34] [35] . Studies from several groups have implicated MDSCs in tumor-associated T-cell tolerance 4, 5 . To understand the mechanism of this process, we have used an experimental model based on adoptive transfer of T cells and MDSCs into naive congenic recipients. Tumor-free recipients enabled us to avoid the various confounding effects of tumor. In both experimental systems tested, MDSCs induced a marked decrease in the binding of specific pMHC to CD8 + T cells. Although this effect has not been described in cancer, it is known that the changes in TCR binding avidity can be important in regulating antigen sensitivity [36] [37] [38] (see Supplementary Discussion online).
Our experiments showed that ROS have a crucial role in MDSCmediated T-cell tolerance. ROS can modify proteins directly or in combination with nitric oxide, contributing to generation of peroxynitrite. Here, a peroxynitrite scavenger completely eliminated MDSCinduced T-cell tolerance. Nitration of tyrosine has long been recognized as a marker of peroxynitrite activity. Peroxynitrite-dependent tyrosine nitration is likely to occur through the initial reaction of peroxynitrite with carbon dioxide or metal centers, leading to secondary nitrating species as nitrogen dioxide radicals 39 . In addition, peroxynitrite can react directly with cysteine, methionine and tryptophan 39 . It is likely that tyrosine nitration represents only part of the total peroxynitrite activity in this experimental system. Molecular modeling identified many tyrosine residues in TCR and CD8 that could be susceptible to nitration, and structural analysis showed that nitration of these residues would result in decreased flexibility and increased rigidity of TCR domains, which might significantly alter the epitope-specific interactions between TCR and pMHC. Our observation of substantially more nitrotyrosine on the surface of antigen-specific CD8 + T cells from mice treated with MDSCs confirmed the antigenic specificity of the tolerance induced by contacts with MDSCs.
These results suggest a previously unknown mechanism of CD8 + T-cell tolerance in cancer and possibly in other pathological conditions associated with MDSC accumulation. MDSCs that accumulate in tumor-bearing hosts contain large amounts of ROS and peroxynitrite. Because these substances are short-lived and highly reactive, they are active only at very short distances. The interface between MDSCs and CD8 + T cells interacting during antigen-TCR recognition provides such an environment. The amount of peroxynitrite produced by MDSCs is sufficient to nitrate tyrosine exposed on the surface of contacting cells. Modified tyrosine on TCR and CD8 alters the conformational flexibility of TCR chains, leading to loss of the response to specific antigen. We suggest that a similar process of tumor-induced peripheral immunological tolerance may potentially operate by using other post-translational modifications of proteins in the TCR-pMHC complex. Such a mechanism may explain the well-established fact that tumor-bearing hosts do not have profound systemic immune deficiency and T cells retain their ability to respond to other stimuli, including viruses, lectins and interleukin 2 (IL-2), among others. Our study provides additional support to the theory of preventing the nitrotyrosine formation in cancer immunotherapy 40 . Blocking peroxynitrite generation or using scavengers could represent an attractive opportunity to decrease or even to eliminate MDSC-induced T-cell tolerance and to enhance the effect of cancer immunotherapy. More potential molecular targets may be discovered if other tumor-induced post-translational modifications of proteins involved in T cell-APC interactions are explored.
METHODS
Mice and reagents. All mouse experiments were approved by the University of South Florida Institutional Animal Care and Use Committee. Female C57BL/6 mice (aged 6-8 weeks) were obtained from the National Cancer Institute. We purchased OT-1 TCR-transgenic mice (C57Bl/6-Tg(TCRaTCRb)1100mjb), gp91 phox-/-(B6.129S6-Cybb tm1Din ), iNOS -/-(C57BL6-Nos2 tm1Lau ) and CD45.1 + congenic mice (B6.SJL-PtrcaPep3b/BoyJ) from Jackson Laboratories. 2C TCR transgenic mice have been described 41 . To establish EL-4 and EG-7 tumors, C57BL/6 mice were injected s.c. with 5 Â 10 5 EL-4 or EG-7 cells, respectively. MC38 tumors were established in C57BL/6 mice by s.c. injection of 3.5 Â 10 5 tumor cells. Tumor size was measured with calipers and is presented as the multiplication of the two longest dimensions. Some EG-7 tumor-bearing mice were treated with daily i.p. injections of uric acid (20 mg in 100 ml of PBS) starting on the day of adoptive transfer of OT-1 cells.
OVA-derived (H-2K b , SIINFEKL), 2C-specific (H-2K b SIY and H-2L d QLSPFPFDL) and control (H-2K b RAHYNIVTF) peptides were obtained from QCB. Incomplete Freud's adjuvant (IFA) and uric acid were purchased from Sigma. We obtained all antibodies used for flow cytometry from BD Pharmingen except anti-nitrotyrosine (Upstate USA Inc.).
Cell isolation and generation. Gr-1 + cells were isolated from spleens of tumorbearing mice by using magnetic beads and MiniMACS columns (Miltenyi Biotec) and biotinylated antibody to Gr-1. More than 98% of Gr-1 + cells were also CD11b + ( Supplementary Fig. 1 ). We isolated T lymphocytes from spleens by using T-cell enrichment columns (R&D Systems), and generated DCs from murine bone marrow using granulocyte-macrophage colony-stimulating factor (Invitrogen) and interleukin-4 (IL-4; R&D Systems) as described 42 . DCs were activated on day 6 of culture by overnight incubation with LPS (1 mg/ml). On day 7, cells were collected and DCs were enriched by centrifugation over Nycoprep A gradient (Accurate Chemicals). To pulse DCs with peptide, cells were washed in PBS and incubated with either specific or control peptide (10 mg/ml) at 37 1C for 2 h.
Adoptive cell transfer and immunization. Naive C57BL/6 recipient mice were injected intravenously (i.v.) with 4-5 Â 10 6 purified T cells from OT-1 or 2C TCR transgenic mice. After 2-3 d, the mice were injected i.v. with 4-5 Â 10 6 MDSCs and within an hour immunized s.c. with 100 mg of specific peptide in IFA. After 10 d, cells from lymph nodes were re-stimulated with specific or control peptide and analyzed ( Supplementary Fig. 1 ).
ELISPOT. We evaluated the number of IFN-g-producing cells in response to stimulation to specific or control peptide (10 mg/ml) by ELISPOT assay as described 43 . Each well contained 2 Â 10 5 lymph nodes cells. The number of spots were counted in triplicates and calculated by an automatic ELISPOT counter (Cellular Technology).
Antigen-binding assay. Fluorescently labeled H2-K b -Ig dimers were prepared as described 36 , cells were incubated with various amounts of dimer (1.20 Â 10 -6 to 6.25 Â 10 -8 M), and dimer binding to T cells was measured by flow cytometry using a FACScalibur (Becton Dickinson). Specific binding of the dimer was calculated by subtracting nonspecific binding (measured using K b -Ig loaded with irrelevant peptide) from the total binding.
CTL assay. Splenocytes were tested in a standard 6-h 51 Cr-release CTL assay. In Figure 1e , the target cells were EL-4 cells loaded with specific or control peptides at the indicated concentrations. Cells were incubated in duplicates at a 25:1 effector/target ratio. The level of nonspecific cytotoxicity (EL-4 target cells loaded with control peptide) was subtracted. Background cytotoxicity was less than 10%. In Figure 6e , splenocytes from EG-7 tumor-bearing mice were stimulated ex vivo for 7 d with SIINFEKL peptide (10 mg/ml), in the presence of IL-15 (10 ng/ml) and IL-21 (10 ng/ml) and used as effectors in a standard 6-h 51 Cr-release CTL assay. Target cells were either EL-4 cells pulsed with 10 mg/ml of either specific (SIINFEKL) or control (RAHYNIVTF) peptides, or EG7 cells. Different effector/target cell ratios were used.
Immunoblotting and immunoprecipitation. T cells were collected, washed in PBS and lysed. Whole-cell lysates were subjected to 10% SDS-PAGE, transferred to PVDF membrane and probed with antibody to nitrotyrosine. Nitrated BSA (NO-BSA) was used as a positive control for nitrotyrosine staining. Bands were visualized by electrochemiluminescence. Chemical reduction of nitrotyrosine was done using sodium dithionite. In some experiments, antibody to CD8 or TCR-b was added to whole-cell lysates (500 mg of protein per sample) and incubated for 2 h at 4 1C. Protein A-Sepharose beads (eBioscience) were then added, and after 1 h the mixture was washed, re-suspended in Laemmli SDS sample buffer and denatured at 95 1C for 5 min. Samples were resolved by 10% SDS-PAGE, transferred to PVDF membrane and probed with antibody to nitrotyrosine, CD8 and TCR-b. Molecular modeling of TCR-H-2K b -peptide complex. We used the Biopolymer module of the SYBYL 7-1 software package (Tripos) to analyze structural effects of TCR nitration on interactions in the pMHC-TCR complex. Crystal structures of the TCR-H-2K b -SIY and TCR-H-2K b -DEV8 complexes (PDB codes: 1G6R, 2CKB and 1MWA) were used as templates for modeling and analysis of intermolecular interactions for both native and nitrated pMHC-TCR complexes. After adding all hydrogen atoms to the crystal structures, the molecular structures were energy-minimized by using the MMFF94s force field implemented in SYBYL. Energy minimizations were performed by 300 cycles of conjugate gradient minimization, and potential hydrogen bonds were visualized and analyzed with Biopolymer.
Confocal microscopy. Splenocytes from OT-1 mice were cultured with specific peptide in the presence of MDSCs (3:1 ratio) on a poly-D-lysine-coated glass-bottom culture dish (MatTek). We labeled the cells with anti-Gr-1-PE, anti-CD8-Alexa 647, anti-nitrotyrosine-Alexa 488 or isotype IgG-Alexa 488. Cells were viewed with a DMI6000 inverted Leica TCS AOBS SP5 tandem scanning confocal microscope with a 40Â, 1.30 NA oil immersion objective. Tunable 488-nm argon and 546-nm and 633-nm laser lines were applied to excite the samples by using AOBS line switching to minimize crosstalk between fluorochromes. Images and z-stacks were produced with three cooled photomultiplier detectors and the LAS AF version 1.5.1.889 software suite.
Note: Supplementary information is available on the Nature Medicine website.
